Levosimendan Reduces Cardiac Troponin Release After Cardiac Surgery: A Meta-analysis of Randomized Controlled Studies

Alberto Zangrillo, Giuseppe Biondi-Zoccai, Anna Mizzi, Giovanna Bruno, Elena Bignami, Chiara Gerli, Vincenzo De Santis, Luigi Tritapepe, Giovanni Landoni

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Objectives: The authors performed a meta-analysis to investigate the effects of levosimendan in cardiac surgery. Inotropic drugs have never shown beneficial effects on outcome in randomized controlled studies, with the possible exception of levosimendan. Design: A meta-analysis. Setting: Hospitals. Participants: A total of 139 patients from 5 randomized controlled studies were included in the analysis. Interventions: None. Measurments and Main Results: Four investigators independently searched BioMedCentral and PubMed. Inclusion criteria were random allocation to treatment, and comparison of levosimendan versus control performed on cardiac surgery patients. Exclusion criteria were duplicate publications, nonhuman experimental studies, and no outcome data. The endpoint was postoperative cardiac troponin release. Levosimendan was associated with a significant reduction in cardiac troponin peak release (weighted mean difference = 2.5 ng/dL [-3.86, -1.14], p = 0.0003) and in time to hospital discharge (weighted mean difference = -1.38 days [-2.78, 0.03], p = 0.05). No other relevant outcome (mortality, myocardial infarction, atrial fibrillation, time on mechanical ventilation, and intensive care unit stay) was improved in those patients receiving levosimendan. Conclusions: Levosimendan has cardioprotective effects, resulting in reduced postoperative cardiac troponin release.

Original languageEnglish
Pages (from-to)474-478
Number of pages5
JournalJournal of Cardiothoracic and Vascular Anesthesia
Volume23
Issue number4
DOIs
Publication statusPublished - Aug 2009

Fingerprint

Troponin
Thoracic Surgery
Meta-Analysis
Duplicate Publication
Random Allocation
Artificial Respiration
PubMed
Atrial Fibrillation
Intensive Care Units
simendan
Myocardial Infarction
Research Personnel
Outcome Assessment (Health Care)
Mortality
Pharmaceutical Preparations

Keywords

  • cardiac biomarker
  • cardiac surgery
  • inotropic drug
  • levosimendan
  • meta-analysis
  • troponin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Anesthesiology and Pain Medicine

Cite this

Levosimendan Reduces Cardiac Troponin Release After Cardiac Surgery : A Meta-analysis of Randomized Controlled Studies. / Zangrillo, Alberto; Biondi-Zoccai, Giuseppe; Mizzi, Anna; Bruno, Giovanna; Bignami, Elena; Gerli, Chiara; De Santis, Vincenzo; Tritapepe, Luigi; Landoni, Giovanni.

In: Journal of Cardiothoracic and Vascular Anesthesia, Vol. 23, No. 4, 08.2009, p. 474-478.

Research output: Contribution to journalArticle

Zangrillo, Alberto ; Biondi-Zoccai, Giuseppe ; Mizzi, Anna ; Bruno, Giovanna ; Bignami, Elena ; Gerli, Chiara ; De Santis, Vincenzo ; Tritapepe, Luigi ; Landoni, Giovanni. / Levosimendan Reduces Cardiac Troponin Release After Cardiac Surgery : A Meta-analysis of Randomized Controlled Studies. In: Journal of Cardiothoracic and Vascular Anesthesia. 2009 ; Vol. 23, No. 4. pp. 474-478.
@article{ef9dc6594d3f44168ac094165144a848,
title = "Levosimendan Reduces Cardiac Troponin Release After Cardiac Surgery: A Meta-analysis of Randomized Controlled Studies",
abstract = "Objectives: The authors performed a meta-analysis to investigate the effects of levosimendan in cardiac surgery. Inotropic drugs have never shown beneficial effects on outcome in randomized controlled studies, with the possible exception of levosimendan. Design: A meta-analysis. Setting: Hospitals. Participants: A total of 139 patients from 5 randomized controlled studies were included in the analysis. Interventions: None. Measurments and Main Results: Four investigators independently searched BioMedCentral and PubMed. Inclusion criteria were random allocation to treatment, and comparison of levosimendan versus control performed on cardiac surgery patients. Exclusion criteria were duplicate publications, nonhuman experimental studies, and no outcome data. The endpoint was postoperative cardiac troponin release. Levosimendan was associated with a significant reduction in cardiac troponin peak release (weighted mean difference = 2.5 ng/dL [-3.86, -1.14], p = 0.0003) and in time to hospital discharge (weighted mean difference = -1.38 days [-2.78, 0.03], p = 0.05). No other relevant outcome (mortality, myocardial infarction, atrial fibrillation, time on mechanical ventilation, and intensive care unit stay) was improved in those patients receiving levosimendan. Conclusions: Levosimendan has cardioprotective effects, resulting in reduced postoperative cardiac troponin release.",
keywords = "cardiac biomarker, cardiac surgery, inotropic drug, levosimendan, meta-analysis, troponin",
author = "Alberto Zangrillo and Giuseppe Biondi-Zoccai and Anna Mizzi and Giovanna Bruno and Elena Bignami and Chiara Gerli and {De Santis}, Vincenzo and Luigi Tritapepe and Giovanni Landoni",
year = "2009",
month = "8",
doi = "10.1053/j.jvca.2008.11.013",
language = "English",
volume = "23",
pages = "474--478",
journal = "Journal of Cardiothoracic and Vascular Anesthesia",
issn = "1053-0770",
publisher = "W B SAUNDERS CO-ELSEVIER INC",
number = "4",

}

TY - JOUR

T1 - Levosimendan Reduces Cardiac Troponin Release After Cardiac Surgery

T2 - A Meta-analysis of Randomized Controlled Studies

AU - Zangrillo, Alberto

AU - Biondi-Zoccai, Giuseppe

AU - Mizzi, Anna

AU - Bruno, Giovanna

AU - Bignami, Elena

AU - Gerli, Chiara

AU - De Santis, Vincenzo

AU - Tritapepe, Luigi

AU - Landoni, Giovanni

PY - 2009/8

Y1 - 2009/8

N2 - Objectives: The authors performed a meta-analysis to investigate the effects of levosimendan in cardiac surgery. Inotropic drugs have never shown beneficial effects on outcome in randomized controlled studies, with the possible exception of levosimendan. Design: A meta-analysis. Setting: Hospitals. Participants: A total of 139 patients from 5 randomized controlled studies were included in the analysis. Interventions: None. Measurments and Main Results: Four investigators independently searched BioMedCentral and PubMed. Inclusion criteria were random allocation to treatment, and comparison of levosimendan versus control performed on cardiac surgery patients. Exclusion criteria were duplicate publications, nonhuman experimental studies, and no outcome data. The endpoint was postoperative cardiac troponin release. Levosimendan was associated with a significant reduction in cardiac troponin peak release (weighted mean difference = 2.5 ng/dL [-3.86, -1.14], p = 0.0003) and in time to hospital discharge (weighted mean difference = -1.38 days [-2.78, 0.03], p = 0.05). No other relevant outcome (mortality, myocardial infarction, atrial fibrillation, time on mechanical ventilation, and intensive care unit stay) was improved in those patients receiving levosimendan. Conclusions: Levosimendan has cardioprotective effects, resulting in reduced postoperative cardiac troponin release.

AB - Objectives: The authors performed a meta-analysis to investigate the effects of levosimendan in cardiac surgery. Inotropic drugs have never shown beneficial effects on outcome in randomized controlled studies, with the possible exception of levosimendan. Design: A meta-analysis. Setting: Hospitals. Participants: A total of 139 patients from 5 randomized controlled studies were included in the analysis. Interventions: None. Measurments and Main Results: Four investigators independently searched BioMedCentral and PubMed. Inclusion criteria were random allocation to treatment, and comparison of levosimendan versus control performed on cardiac surgery patients. Exclusion criteria were duplicate publications, nonhuman experimental studies, and no outcome data. The endpoint was postoperative cardiac troponin release. Levosimendan was associated with a significant reduction in cardiac troponin peak release (weighted mean difference = 2.5 ng/dL [-3.86, -1.14], p = 0.0003) and in time to hospital discharge (weighted mean difference = -1.38 days [-2.78, 0.03], p = 0.05). No other relevant outcome (mortality, myocardial infarction, atrial fibrillation, time on mechanical ventilation, and intensive care unit stay) was improved in those patients receiving levosimendan. Conclusions: Levosimendan has cardioprotective effects, resulting in reduced postoperative cardiac troponin release.

KW - cardiac biomarker

KW - cardiac surgery

KW - inotropic drug

KW - levosimendan

KW - meta-analysis

KW - troponin

UR - http://www.scopus.com/inward/record.url?scp=67650545459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650545459&partnerID=8YFLogxK

U2 - 10.1053/j.jvca.2008.11.013

DO - 10.1053/j.jvca.2008.11.013

M3 - Article

C2 - 19217315

AN - SCOPUS:67650545459

VL - 23

SP - 474

EP - 478

JO - Journal of Cardiothoracic and Vascular Anesthesia

JF - Journal of Cardiothoracic and Vascular Anesthesia

SN - 1053-0770

IS - 4

ER -